搜尋結果
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). [29] Medical uses. The Novavax COVID‑19 vaccine is indicated for active immunization to prevent COVID‑19 caused by SARS-CoV-2. [4]
- AU: B1
- Intramuscular
- Covovax, Nuvaxovid
- SARS-CoV-2
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases.
- 1987; 36 years ago
- Gaithersburg, Maryland, U.S.
- 1,541 (2022)
- US$1.982 billion (2022)
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (), the virus that causes coronavirus disease 2019 ().Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome and Middle East respiratory ...
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Full (4) Australia Canada Japan South Korea
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine ...
e. The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [33] [34] [35] using as a vector the modified chimpanzee ...
COVID-19 vaccine vial prop A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.
